G
Glenn M. Chertow
Researcher at Stanford University
Publications - 830
Citations - 94517
Glenn M. Chertow is an academic researcher from Stanford University. The author has contributed to research in topics: Kidney disease & Dialysis. The author has an hindex of 128, co-authored 764 publications receiving 82401 citations. Previous affiliations of Glenn M. Chertow include University of Groningen & Fresenius Medical Care.
Papers
More filters
Journal ArticleDOI
Vitamin D deficiency and frailty in older Americans.
TL;DR: Vitamin D deficiency and frailty in older Americans is found to be a major risk factor for disease and disability in these older Americans.
Journal ArticleDOI
Acute renal failure after endovascular vs open repair of abdominal aortic aneurysm.
Ron Wald,Ron Wald,Sushrut S. Waikar,Orfeas Liangos,Brian J.G. Pereira,Glenn M. Chertow,Bertrand L. Jaber +6 more
TL;DR: Compared with open AAA repair, EVAR is associated with a lower risk of postprocedure acute renal failure and acute kidney failure requiring hemodialysis.
Journal ArticleDOI
Is the Administration of Dopamine Associated with Adverse or Favorable Outcomes in Acute Renal Failure
TL;DR: There is insufficient evidence that the administration of low-dose dopamine improves survival or obviates the need for dialysis in persons with acute renal failure, and the routine use ofLow- dose dopamine should be discouraged until a prospective, randomized, placebo-controlled trial establishes its safety and efficacy.
Journal ArticleDOI
Diuretics, mortality, and nonrecovery of renal function in acute renal failure
Journal ArticleDOI
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
Hiddo J.L. Heerspink,Hiddo J.L. Heerspink,Bergur V. Stefánsson,Glenn M. Chertow,Ricardo Correa-Rotter,Tom Greene,Fan Fan Hou,Magnus Lindberg,John J.V. McMurray,Peter Rossing,Peter Rossing,R D Toto,Anna Maria Langkilde,David C. Wheeler,David C. Wheeler,Dapa-Ckd Investigators,Dapa-Ckd Investigators +16 more
TL;DR: DAPA-CKD will determine whether the SGLT2 inhibitor dapagliflozin, added to guideline-recommended therapies, safely reduces the rate of renal and cardiovascular events in patients across multiple CKD stages with and without diabetes.